Kiniksa Pharma Files Proxy Materials

Ticker: KNSA · Form: DEFA14A · Filed: May 9, 2025 · CIK: 1730430

Kiniksa Pharmaceuticals International, PLC DEFA14A Filing Summary
FieldDetail
CompanyKiniksa Pharmaceuticals International, PLC (KNSA)
Form TypeDEFA14A
Filed DateMay 9, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: proxy-filing, governance

TL;DR

Kiniksa Pharma filed proxy docs, get ready for shareholder votes.

AI Summary

Kiniksa Pharmaceuticals International, plc filed a Definitive Additional Materials proxy statement on May 9, 2025. This filing relates to the company's proxy materials, which are typically used for shareholder meetings to vote on corporate matters. The company is incorporated in X0 and its fiscal year ends on December 31st.

Why It Matters

This filing indicates that Kiniksa Pharmaceuticals is proceeding with corporate governance procedures, likely involving shareholder votes on important company decisions.

Risk Assessment

Risk Level: low — This is a routine proxy filing and does not contain new financial information or strategic changes that would immediately impact risk.

Key Players & Entities

FAQ

What type of filing is this?

This is a Definitive Additional Materials proxy statement (DEFA14A).

Who is the filing company?

The filing company is Kiniksa Pharmaceuticals International, plc.

When was this filing made?

The filing was made on May 9, 2025.

What is the company's Standard Industrial Classification code?

The SIC code is 2834, which corresponds to Pharmaceutical Preparations.

What is the company's business address?

The business address is 23 Old Bond Street, Floor 3, London, WIS 4PZ.

Filing Details

This Form DEFA14A (Form DEFA14A) was filed with the SEC on May 9, 2025 regarding Kiniksa Pharmaceuticals International, plc (KNSA).

View full filing on EDGAR

View Full Filing

View this DEFA14A filing on SEC EDGAR

View on Read The Filing